Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

Stefano Fais; Lorraine O'Driscoll; Francesc E. Borras; Edit Buzas; Giovanni Camussi; Francesco Cappello; Joana Carvalho; Anabela Cordeiro Da Silva; Hernando Del Portillo; Samir El Andaloussi; Tanja Ficko Trček; Roberto Furlan; An Hendrix; Ihsan Gursel; Veronika Kralj-Iglic; Bertrand Kaeffer; Maja Kosanovic; Marilena E. Lekka; Georg Lipps; Mariantonia Logozzi; Antonio Marcilla; Marei Sammar; Alicia Llorente; Irina Nazarenko; Carla Oliveira; Gabriella Pocsfalvi; Lawrence Rajendran; Graça Raposo; Eva Rohde; Pia Siljander; Guillaume Van Niel; M. Helena Vasconcelos; María Yáñez-Mó; Marjo L. Yliperttula; Natasa Zarovni; Apolonija Bedina Zavec; Bernd Giebel

doi:10.1021/acsnano.5b08015

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

Stefano Fais, Lorraine O'Driscoll, Francesc E. Borras, Edit Buzas, Giovanni Camussi, Francesco Cappello, Joana Carvalho, Anabela Cordeiro Da Silva, Hernando Del Portillo, Samir El Andaloussi, Tanja Ficko Trček, Roberto Furlan, An Hendrix, Ihsan Gursel, Veronika Kralj-Iglic, Bertrand Kaeffer, Maja Kosanovic, Marilena E. Lekka, Georg Lipps, Mariantonia LogozziAntonio Marcilla, Marei Sammar, Alicia Llorente, Irina Nazarenko, Carla Oliveira, Gabriella Pocsfalvi, Lawrence Rajendran, Graça Raposo, Eva Rohde, Pia Siljander, Guillaume Van Niel, M. Helena Vasconcelos, María Yáñez-Mó, Marjo L. Yliperttula, Natasa Zarovni, Apolonija Bedina Zavec, Bernd Giebel

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Review article › peer-review

Abstract

Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.

Original language	English
Pages (from-to)	3886-3899
Number of pages	14
Journal	ACS Nano
Volume	10
Issue number	4
DOIs	https://doi.org/10.1021/acsnano.5b08015
Publication status	Published - Apr 26 2016

ASJC Scopus subject areas

Engineering(all)
Materials Science(all)
Physics and Astronomy(all)

Access to Document

10.1021/acsnano.5b08015

Cite this

Fais, S., O'Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro Da Silva, A., Del Portillo, H., El Andaloussi, S., Ficko Trček, T., Furlan, R., Hendrix, A., Gursel, I., Kralj-Iglic, V., Kaeffer, B., Kosanovic, M., Lekka, M. E., Lipps, G., ... Giebel, B. (2016). Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 10(4), 3886-3899. https://doi.org/10.1021/acsnano.5b08015

Fais, S, O'Driscoll, L, Borras, FE, Buzas, E, Camussi, G, Cappello, F, Carvalho, J, Cordeiro Da Silva, A, Del Portillo, H, El Andaloussi, S, Ficko Trček, T, Furlan, R, Hendrix, A, Gursel, I, Kralj-Iglic, V, Kaeffer, B, Kosanovic, M, Lekka, ME, Lipps, G, Logozzi, M, Marcilla, A, Sammar, M, Llorente, A, Nazarenko, I, Oliveira, C, Pocsfalvi, G, Rajendran, L, Raposo, G, Rohde, E, Siljander, P, Van Niel, G, Vasconcelos, MH, Yáñez-Mó, M, Yliperttula, ML, Zarovni, N, Zavec, AB & Giebel, B 2016, 'Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine', ACS Nano, vol. 10, no. 4, pp. 3886-3899. https://doi.org/10.1021/acsnano.5b08015

@article{e107e668d0774c2d8a23cd620cff7cc2,

title = "Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine",

abstract = "Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.",

author = "Stefano Fais and Lorraine O'Driscoll and Borras, {Francesc E.} and Edit Buzas and Giovanni Camussi and Francesco Cappello and Joana Carvalho and {Cordeiro Da Silva}, Anabela and {Del Portillo}, Hernando and {El Andaloussi}, Samir and {Ficko Tr{\v c}ek}, Tanja and Roberto Furlan and An Hendrix and Ihsan Gursel and Veronika Kralj-Iglic and Bertrand Kaeffer and Maja Kosanovic and Lekka, {Marilena E.} and Georg Lipps and Mariantonia Logozzi and Antonio Marcilla and Marei Sammar and Alicia Llorente and Irina Nazarenko and Carla Oliveira and Gabriella Pocsfalvi and Lawrence Rajendran and Gra{\c c}a Raposo and Eva Rohde and Pia Siljander and {Van Niel}, Guillaume and Vasconcelos, {M. Helena} and Mar{\'i}a Y{\'a}{\~n}ez-M{\'o} and Yliperttula, {Marjo L.} and Natasa Zarovni and Zavec, {Apolonija Bedina} and Bernd Giebel",

year = "2016",

month = apr,

day = "26",

doi = "10.1021/acsnano.5b08015",

language = "English",

volume = "10",

pages = "3886--3899",

journal = "ACS Nano",

issn = "1936-0851",

publisher = "American Chemical Society",

number = "4",

}

TY - JOUR

T1 - Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

AU - Fais, Stefano

AU - O'Driscoll, Lorraine

AU - Borras, Francesc E.

AU - Buzas, Edit

AU - Camussi, Giovanni

AU - Cappello, Francesco

AU - Carvalho, Joana

AU - Cordeiro Da Silva, Anabela

AU - Del Portillo, Hernando

AU - El Andaloussi, Samir

AU - Ficko Trček, Tanja

AU - Furlan, Roberto

AU - Hendrix, An

AU - Gursel, Ihsan

AU - Kralj-Iglic, Veronika

AU - Kaeffer, Bertrand

AU - Kosanovic, Maja

AU - Lekka, Marilena E.

AU - Lipps, Georg

AU - Logozzi, Mariantonia

AU - Marcilla, Antonio

AU - Sammar, Marei

AU - Llorente, Alicia

AU - Nazarenko, Irina

AU - Oliveira, Carla

AU - Pocsfalvi, Gabriella

AU - Rajendran, Lawrence

AU - Raposo, Graça

AU - Rohde, Eva

AU - Siljander, Pia

AU - Van Niel, Guillaume

AU - Vasconcelos, M. Helena

AU - Yáñez-Mó, María

AU - Yliperttula, Marjo L.

AU - Zarovni, Natasa

AU - Zavec, Apolonija Bedina

AU - Giebel, Bernd

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.

AB - Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.

UR - http://www.scopus.com/inward/record.url?scp=84968866526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968866526&partnerID=8YFLogxK

U2 - 10.1021/acsnano.5b08015

DO - 10.1021/acsnano.5b08015

M3 - Review article

AN - SCOPUS:84968866526

VL - 10

SP - 3886

EP - 3899

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 4

ER -

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this